Literature DB >> 8833052

The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates.

E Yelin1.   

Abstract

We determined the average medical and indirect costs of rheumatoid arthritis (RA) from clinical and community based samples and compared those costs to those experienced by similar persons without RA. We reviewed the literature and analyzed the UCSF RA Panel Study and the National Health Interview Survey for the years 1989-91. The annual medical care costs of RA ranged from $4,300 to $5,700 in 1994 terms in the clinical samples, with hospital admissions accounting for half to two-thirds of the total. Indirect costs in the clinical samples exceeded direct costs and ranged from just under $10,000 to more than $16,000 a year. Medical care costs of RA are highly skewed, with persons in the 90th percentile experiencing costs more than 100 times as large as those in the 10th. In the national community based sample, the costs of RA amounted to $8.74 billion, of which more than half was due to medical care. In this sample, the increment of costs experienced by persons with RA compared to those without was $3.07 billion, with 80% of the excess the result of indirect costs due to wage losses.

Entities:  

Mesh:

Year:  1996        PMID: 8833052

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN: 0380-0903


  21 in total

1.  The case for stratified cost-effectiveness analysis by baseline health-related QOL: theory and sensitivity analysis.

Authors:  Joseph Schaafsma
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 2.  International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review.

Authors:  Hubertus Rosery; Rito Bergemann; Stefanie Maxion-Bergemann
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK.

Authors:  Marco Barbieri; John B Wong; Michael Drummond
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

4.  Influence of rheumatoid arthritis-related morning stiffness on productivity at work: results from a survey in 11 European countries.

Authors:  Kalle Mattila; Frank Buttgereit; Risto Tuominen
Journal:  Rheumatol Int       Date:  2015-05-26       Impact factor: 2.631

5.  Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income: experience from the FIN-RACo trial.

Authors:  K Puolakka; H Kautiainen; M Pekurinen; T Möttönen; P Hannonen; M Korpela; M Hakala; M Arkela-Kautiainen; R Luukkainen; M Leirisalo-Repo
Journal:  Ann Rheum Dis       Date:  2005-11-16       Impact factor: 19.103

6.  Sensory and vascular changes in a rat monoarthritis model: prophylactic and therapeutic effects of meloxicam.

Authors:  Javeria Ali Hashmi; Kiran Yashpal; David W Holdsworth; James L Henry
Journal:  Inflamm Res       Date:  2010-03-28       Impact factor: 4.575

7.  Health-related quality of life in young adult patients with rheumatoid arthritis in Iran: reliability and validity of the Persian translation of the PedsQL™ 4.0 Generic Core Scales Young Adult Version.

Authors:  Amir H Pakpour; Isa Mohammadi Zeidi; Fariba Hashemi; Mohsen Saffari; Andrea Burri
Journal:  Clin Rheumatol       Date:  2012-09-11       Impact factor: 2.980

8.  The impact of rheumatoid arthritis and biologics on employers and payers.

Authors:  Paresh Chaudhari
Journal:  Biotechnol Healthc       Date:  2008-07

9.  Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients.

Authors:  A Boonen; A Chorus; H Miedema; D van der Heijde; H van der Tempel; S van der Linden
Journal:  Ann Rheum Dis       Date:  2001-04       Impact factor: 19.103

10.  Evaluation of the effect of anti-tumor necrosis factor agent use on rheumatoid arthritis work disability: the jury is still out.

Authors:  Saralynn Allaire; Frederick Wolfe; Jingbo Niu; Yuqing Zhang; Bin Zhang; Michael LaValley
Journal:  Arthritis Rheum       Date:  2008-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.